{"protocolSection": {"identificationModule": {"nctId": "NCT04092816", "orgStudyIdInfo": {"id": "LCCC1920"}, "secondaryIdInfos": [{"id": "5K07CA218167-02", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/5K07CA218167-02"}], "organization": {"fullName": "UNC Lineberger Comprehensive Cancer Center", "class": "OTHER"}, "briefTitle": "Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention", "officialTitle": "The Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention for Families Affected by Parental Cancer", "acronym": "FAMILY"}, "statusModule": {"statusVerifiedDate": "2023-08", "overallStatus": "TERMINATED", "whyStopped": "The study was stopped prematurely due to difficulty meeting accrual and retention goals, exacerbated by the COVID-19 pandemic.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-10-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-06-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-06-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-09-04", "studyFirstSubmitQcDate": "2019-09-16", "studyFirstPostDateStruct": {"date": "2019-09-17", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-04-17", "resultsFirstSubmitQcDate": "2023-08-17", "resultsFirstPostDateStruct": {"date": "2023-08-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-08-17", "lastUpdatePostDateStruct": {"date": "2023-08-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "UNC Lineberger Comprehensive Cancer Center", "class": "OTHER"}, "collaborators": [{"name": "National Cancer Institute (NCI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This is a single-arm pilot study to evaluate the feasibility and acceptability of a novel psychosocial intervention to improve psychosocial outcomes for parents with advanced cancer and their co-parents. In this single-center study, we will recruit ten mothers with metastatic breast cancer and their co-parents as dyads (N=20) to participate in the Fathers and Mothers Invested in the Lives of their Youth (FAMILY) intervention. Patient and co-parent dyads will participate in 2-3 study visits with an intervention facilitator and a post-intervention feedback interview. Participants will also complete baseline and follow-up study surveys. The final products of this study will be the FAMILY intervention manual and training materials, and fidelity assessments.", "detailedDescription": "Cancer is the leading disease-specific cause of early parental death in the United States and having dependent children worsens suffering for parents with advanced cancer and their families. The FAMILY intervention consists of manualized visits with a trained intervention facilitator and psychoeducation materials to help parents cope with cancer-related parenting concerns. The purpose of the intervention is to improve parenting concerns, emotional well-being, and end-of-life (EOL) preparation among participants. This study will evaluate whether a psychosocial intervention to reduce psychological distress and improve EOL preparation for mothers with metastatic breast cancer and their co-parents can be acceptable, feasible, and relevant to the target patient population.\n\nThis study is needed in order to generate critical data to: (1) refine the intervention in preparation for a pilot efficacy randomized controlled trial (RCT); and to generate preliminary data demonstrating the feasibility and acceptability of core intervention components. The preliminary data will support future grant applications for a full-scale efficacy RCT."}, "conditionsModule": {"conditions": ["Metastatic Breast Cancer", "Parenting"], "keywords": ["Parenting"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "interventionModelDescription": "10 patient and co-parent dyads (20 participants in total) will participate in the pilot study to evaluate the feasibility and acceptability of the FAMILY intervention. Preliminary effects of the intervention will also be examined.", "primaryPurpose": "SUPPORTIVE_CARE", "maskingInfo": {"masking": "NONE", "maskingDescription": "Because this is a pilot study, all participant dyads will receive the same intervention and no blinding will take place."}}, "enrollmentInfo": {"count": 15, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "FAMILY", "type": "EXPERIMENTAL", "description": "Patient-co-parent dyads will participate in the FAMILY intervention in-person.", "interventionNames": ["Behavioral: FAMILY Intervention"]}], "interventions": [{"type": "BEHAVIORAL", "name": "FAMILY Intervention", "description": "The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials.", "armGroupLabels": ["FAMILY"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Acceptability of the Intervention", "description": "Acceptability of the intervention was defined as the number of participants who completed the study intervention. Participants' experience was assessed qualitatively, using post-intervention interviews.", "timeFrame": "42 Days"}, {"measure": "Acceptability of the Intervention Measured by the Study Visit Assessment Form", "description": "The acceptability of the intervention was assessed through participants' satisfaction with the program. The Lyon Satisfaction questionnaire consists of 5-point Likert-type items assessing positive (six items) and negative (seven items) emotional reactions to the study visit. Responses were summed and reported for each subscale with higher scores meaning higher emotional reactions, and worse reactions. Positive subscale: 6-30 and negative subscale: 7-35.", "timeFrame": "7 Days"}, {"measure": "Feasibility of Study Procedures", "description": "Feasibility of study procedures were assessed how likely patient-co-parent dyads are to join the study through tracking the number of eligible dyads who participate in the study.", "timeFrame": "14 Days"}, {"measure": "Feasibility of Recruitment", "description": "Assess how likely patient-co-parent dyads are to join the study by tracking the number of eligible dyads who participate in the study.", "timeFrame": "Baseline"}], "secondaryOutcomes": [{"measure": "Feasibility of Completion", "description": "Feasibility of Completion was evaluated by tracking the number of dyads that complete the study visits and study assessments. Numbers reflect from Baseline through 42 days given a flexible duration of intervention.", "timeFrame": "Up to 42 Days"}, {"measure": "Emotional Well-being Measured by the Functional Assessment of Chronic Illness Therapy - Palliative Care (FACIT-Pal Care) Subscale", "description": "Assess the change in patient's emotional well-being through the FACIT-Pal Care; a 6-item self-report assessment of emotional well-being that is widely used in palliative care research. Score range is 0-24, higher scores indicate better emotional well-being.", "timeFrame": "Baseline, 7 Days, 14 Days, 28 Days, 42 Days"}, {"measure": "Anxiety and Depression Symptoms Measured by the Hospital Anxiety and Depression Scale (HADS)", "description": "Assess the change in patient and co-parent's depression and anxiety symptom severity. The HADS consists of two 7-item subscales assessing depression and anxiety symptoms separately. Score range for each subscale is 0-21, higher scores indicate greater symptoms.", "timeFrame": "Baseline, 7 Days, 14 Days, 28 Days, 42 Days"}, {"measure": "Parenting Concerns Measured by the Parenting Concerns Questionnaire-Advanced Disease (PCQ-AD)", "description": "Assess the change in patient and co-parent's parenting concerns severity. The PCQ-AD is an investigator-adapted measure of parenting concerns measured on a 4-point scale. Total score range for the PCQ-AD is 0-3 with higher scores indicating greater distress.", "timeFrame": "Baseline, 7 Days, 14 Days, 28 Days, 42 Days"}, {"measure": "The Change in Patient and Co-parent's Illness-related Communication", "description": "The change in patient and co-parent's illness-related communication was measured by the Couples Illness Communication Scale (CICS).\n\nThe CICS is a brief self-report measure of illness-related couple communication. The CICS consists of 4 items measured on a 5-point Likert-type scale. Total Score Range: 4-20, Higher is better.", "timeFrame": "Baseline, 7 Days, 14 Days, 28 Days, 42 Days"}, {"measure": "Patient's Health-related Quality of Life", "description": "Patient Health-related Quality of Life was assessed change in the patient's health-related quality of life measured by the Functional Assessment of Chronic Illness Therapy - Palliative Care (FACIT-Pal).\n\nThe FACIT-Pal is a 46-item self-administered assessment of general HRQOL in cancer patients. It is graded on a 4-point scale and higher scores indicate better quality of life. Total Score Range: 0-184\n\nAssess change in the patient's health-related quality of life measured by the FACIT-Pal; the FACIT-Pal is a 46-item self-administered assessment of general HRQOL in cancer patients. It is graded on a 4-point scale and higher scores indicate better quality of life.\n\nThe numbers analyzed reflect all individuals who contributed data at each time point.", "timeFrame": "Baseline, 7 Days, 14 Days, 28 Days, 42 Days"}, {"measure": "Patient and Co-parent's Cancer-related Family Communication", "description": "Patient and Co-Parent's Cancer-related Family Communication was assessed changes in the patient and co-parent's scores for a nine-item investigator-developed measure.\n\nThe measure assesses participants' confidence and preparation to engage in communication about the impact of parental cancer on children. For the first 8 items, the score range is on a 4-point scale (1 to 4). The last item is graded on a 3-point scale (1 to 3). For all 9 items, higher is better. Due to the small sample size, each individual score item was reported.", "timeFrame": "Baseline, 7 Days, 14 Days, 28 Days, 42 Days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria for patients:\n\n* Be a woman with metastatic (stage IV) breast cancer who has either: (1) estrogen (ER), progesterone (PR), or HER2 receptor-negative cancer and disease progression beyond first line of therapy, or (2) ER, PR, or HER2 -positive cancer and disease progression beyond two lines of therapy;\n* A mother of at least one dependent child, defined as a child \\<18 years of age who lives at least half-time in the home;\n* Be at least 18 years of age;\n* Adequate stamina to complete at least two study visits\n* Able to provide informed consent\n* Able to complete all study measures and visits in English;\n* Be willing to participate in study visits at the North Carolina Cancer Hospital (NCCH) if they live \\>75 miles away from NCCH\n* Have an identified co-parent who is eligible and willing to participate in the study.\n\nInclusion Criteria for Co-parents:\n\n* Be an adult man or woman who is both a partners or spouse of the patient and who would serve as the child(ren)'s primary caregiver if the patient were to become unavailable;\n* Able to provide informed consent;\n* Able to complete all study measures and visits in English;\n* Stated willingness to comply with all study procedures; and\n* Be at least 18 years of age.\n\nExclusion Criteria for patients and co-parents:\n\n* Unable to participate in study visits due to illiteracy, inability to speak English or other causes.\n* Live more than 75-miles away from the North Carolina Cancer Hospital (NCCH) and unable to attend study visits at NCCH (participants who live more than 75-miles away and can attend study visits at NCCH remain eligible for participation).\n* Unwilling to be audio-recorded during facilitated study visits and feedback interview.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "99 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Zev M Nakamura, MD", "affiliation": "University of North Carolina", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill", "city": "Chapel Hill", "state": "North Carolina", "zip": "27599", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "UNC Lineberger Comprehensive Cancer Center Clinical Trials", "url": "http://unclineberger.org/patientcare/clinical-trials/"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 15 subjects (8 patients and 7 co-parents) consented and were found eligible for the study.", "recruitmentDetails": "Participants were recruited from 10/30/2019 through 01/25/2022 at one cancer center in North Carolina.", "groups": [{"id": "FG000", "title": "Patients", "description": "Subjects who are diagnosed with cancer."}, {"id": "FG001", "title": "Co-parents", "description": "Subjects who are spouses of patients with cancer."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Eight patients and 7 co-parents consented.", "groups": [{"id": "BG000", "title": "Patient", "description": "Subjects who are diagnosed with cancer."}, {"id": "BG001", "title": "Co-parent", "description": "Subjects who are spouses of patients with cancer."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "15"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.75", "spread": "8.65"}, {"groupId": "BG001", "value": "45.67", "spread": "10.21"}, {"groupId": "BG002", "value": "42.86", "spread": "9.31"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "12"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "15"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Acceptability of the Intervention", "description": "Acceptability of the intervention was defined as the number of participants who completed the study intervention. Participants' experience was assessed qualitatively, using post-intervention interviews.", "populationDescription": "The number of total participants who started the intervention and completed post-intervention semi-structured interview.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "42 Days", "groups": [{"id": "OG000", "title": "FAMILY", "description": "Patient-co-parent dyads will participate in the FAMILY intervention in-person.\n\nFAMILY Intervention: The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"title": "The patient and co-parent started the study.", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}]}]}, {"title": "The patient and co-parent completed a post-intervention interview.", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}]}]}]}, {"type": "PRIMARY", "title": "Acceptability of the Intervention Measured by the Study Visit Assessment Form", "description": "The acceptability of the intervention was assessed through participants' satisfaction with the program. The Lyon Satisfaction questionnaire consists of 5-point Likert-type items assessing positive (six items) and negative (seven items) emotional reactions to the study visit. Responses were summed and reported for each subscale with higher scores meaning higher emotional reactions, and worse reactions. Positive subscale: 6-30 and negative subscale: 7-35.", "populationDescription": "10 Subjects completed the study visit assessment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "7 Days", "groups": [{"id": "OG000", "title": "FAMILY", "description": "Patient-co-parent dyads will participate in the FAMILY intervention in-person.\n\nFAMILY Intervention: The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"title": "Positive emotions", "categories": [{"measurements": [{"groupId": "OG000", "value": "26.6", "spread": "5.3"}]}]}, {"title": "Negative emotions", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.7", "spread": "2.8"}]}]}]}, {"type": "PRIMARY", "title": "Feasibility of Study Procedures", "description": "Feasibility of study procedures were assessed how likely patient-co-parent dyads are to join the study through tracking the number of eligible dyads who participate in the study.", "populationDescription": "The number of participants (patient and co-parent) who started the intervention.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "14 Days", "groups": [{"id": "OG000", "title": "Patients", "description": "Subjects who are diagnosed with cancer."}, {"id": "OG001", "title": "Co-parents", "description": "Subjects who are spouses of patients with cancer."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}]}], "classes": [{"title": "Started", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Completed", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "PRIMARY", "title": "Feasibility of Recruitment", "description": "Assess how likely patient-co-parent dyads are to join the study by tracking the number of eligible dyads who participate in the study.", "populationDescription": "All 18 participants/co-parents were approached by the study team.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Patients", "description": "Subjects with a cancer diagnosis."}, {"id": "OG001", "title": "Co-parents", "description": "Subjects who are spouse of a patient with cancer diagnosis."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"title": "Eligible", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Consented", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "7"}]}]}]}, {"type": "SECONDARY", "title": "Feasibility of Completion", "description": "Feasibility of Completion was evaluated by tracking the number of dyads that complete the study visits and study assessments. Numbers reflect from Baseline through 42 days given a flexible duration of intervention.", "populationDescription": "The number of participants (patient and co-parent) consented and completed study visits.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 42 Days", "groups": [{"id": "OG000", "title": "Patiens", "description": "Subjects who are diagnosed with cancer."}, {"id": "OG001", "title": "Co-parents", "description": "Subjects who are spouses of patients with cancer."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "7"}]}], "classes": [{"title": "Enrolled", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "7 days", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "14 days", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "28 days", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "42 days", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Emotional Well-being Measured by the Functional Assessment of Chronic Illness Therapy - Palliative Care (FACIT-Pal Care) Subscale", "description": "Assess the change in patient's emotional well-being through the FACIT-Pal Care; a 6-item self-report assessment of emotional well-being that is widely used in palliative care research. Score range is 0-24, higher scores indicate better emotional well-being.", "populationDescription": "Baseline, patient participants only", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 7 Days, 14 Days, 28 Days, 42 Days", "groups": [{"id": "OG000", "title": "FAMILY", "description": "Patient-co-parent dyads will participate in the FAMILY intervention in-person.\n\nFAMILY Intervention: The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "16.4", "spread": "4.3"}]}]}, {"title": "7 days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.0", "spread": "4.5"}]}]}, {"title": "14 days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.7", "spread": "1.2"}]}]}, {"title": "28 days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20.5", "spread": "2.1"}]}]}, {"title": "42 days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Anxiety and Depression Symptoms Measured by the Hospital Anxiety and Depression Scale (HADS)", "description": "Assess the change in patient and co-parent's depression and anxiety symptom severity. The HADS consists of two 7-item subscales assessing depression and anxiety symptoms separately. Score range for each subscale is 0-21, higher scores indicate greater symptoms.", "populationDescription": "Numbers analyzed reflect participants at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, 7 Days, 14 Days, 28 Days, 42 Days", "groups": [{"id": "OG000", "title": "FAMILY", "description": "Patient-co-parent dyads will participate in the FAMILY intervention in-person.\n\nFAMILY Intervention: The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"title": "Baseline Anxiety", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.6", "spread": "2.8"}]}]}, {"title": "Baseline Depression", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.1", "spread": "3.8"}]}]}, {"title": "7 Days Anxiety", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.1", "spread": "2.4"}]}]}, {"title": "7 Days Depression", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.7", "spread": "4.3"}]}]}, {"title": "14 Days Anxiety", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.0", "spread": "1.7"}]}]}, {"title": "14 Days Depression", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.0", "spread": "4.3"}]}]}, {"title": "28 Days Anxiety", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.3", "spread": "2.2"}]}]}, {"title": "28 Days Depression", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "spread": "2.2"}]}]}, {"title": "42 Days Anxiety", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "42 Days Depression", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Parenting Concerns Measured by the Parenting Concerns Questionnaire-Advanced Disease (PCQ-AD)", "description": "Assess the change in patient and co-parent's parenting concerns severity. The PCQ-AD is an investigator-adapted measure of parenting concerns measured on a 4-point scale. Total score range for the PCQ-AD is 0-3 with higher scores indicating greater distress.", "populationDescription": "Number analyzed reflects the number of participants at each time point contributing data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, 7 Days, 14 Days, 28 Days, 42 Days", "groups": [{"id": "OG000", "title": "FAMILY", "description": "Patient-co-parent dyads will participate in the FAMILY intervention in-person.\n\nFAMILY Intervention: The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.8", "spread": "0.6"}]}]}, {"title": "7 Days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "0.7"}]}]}, {"title": "14 Days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "0.6"}]}]}, {"title": "28 Days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.1", "spread": "0.4"}]}]}, {"title": "42 Days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "The Change in Patient and Co-parent's Illness-related Communication", "description": "The change in patient and co-parent's illness-related communication was measured by the Couples Illness Communication Scale (CICS).\n\nThe CICS is a brief self-report measure of illness-related couple communication. The CICS consists of 4 items measured on a 5-point Likert-type scale. Total Score Range: 4-20, Higher is better.", "populationDescription": "Numbers reflect participants at each time point given flexible duration of intervention.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, 7 Days, 14 Days, 28 Days, 42 Days", "groups": [{"id": "OG000", "title": "FAMILY", "description": "Patient-co-parent dyads will participate in the FAMILY intervention in-person.\n\nFAMILY Intervention: The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12.5", "spread": "3.0"}]}]}, {"title": "7 Days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14.1", "spread": "2.2"}]}]}, {"title": "14 Days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.6", "spread": "4.5"}]}]}, {"title": "28 Days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14.3", "spread": "4.4"}]}]}, {"title": "42 Days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Patient's Health-related Quality of Life", "description": "Patient Health-related Quality of Life was assessed change in the patient's health-related quality of life measured by the Functional Assessment of Chronic Illness Therapy - Palliative Care (FACIT-Pal).\n\nThe FACIT-Pal is a 46-item self-administered assessment of general HRQOL in cancer patients. It is graded on a 4-point scale and higher scores indicate better quality of life. Total Score Range: 0-184\n\nAssess change in the patient's health-related quality of life measured by the FACIT-Pal; the FACIT-Pal is a 46-item self-administered assessment of general HRQOL in cancer patients. It is graded on a 4-point scale and higher scores indicate better quality of life.\n\nThe numbers analyzed reflect all individuals who contributed data at each time point.", "populationDescription": "Only patient participants completed the measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, 7 Days, 14 Days, 28 Days, 42 Days", "groups": [{"id": "OG000", "title": "FAMILY", "description": "Patient-co-parent dyads will participate in the FAMILY intervention in-person.\n\nFAMILY Intervention: The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "122.8", "spread": "36.1"}]}]}, {"title": "7 Days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "122.8", "spread": "44.4"}]}]}, {"title": "14 Days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "138.7", "spread": "24.1"}]}]}, {"title": "28 Days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "162.5", "spread": "0.7"}]}]}, {"title": "42 Days", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Patient and Co-parent's Cancer-related Family Communication", "description": "Patient and Co-Parent's Cancer-related Family Communication was assessed changes in the patient and co-parent's scores for a nine-item investigator-developed measure.\n\nThe measure assesses participants' confidence and preparation to engage in communication about the impact of parental cancer on children. For the first 8 items, the score range is on a 4-point scale (1 to 4). The last item is graded on a 3-point scale (1 to 3). For all 9 items, higher is better. Due to the small sample size, each individual score item was reported.", "populationDescription": "Numbers analyzed reflect all participants who contributed data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, 7 Days, 14 Days, 28 Days, 42 Days", "groups": [{"id": "OG000", "title": "FAMILY", "description": "Patient-co-parent dyads will participate in the FAMILY intervention in-person.\n\nFAMILY Intervention: The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"title": "Baseline - comfort talking with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.8", "spread": "1.0"}]}]}, {"title": "Baseline - comfort talking with partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.7", "spread": "0.5"}]}]}, {"title": "Baseline - comfort talking about children's future needs", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.4", "spread": "1.0"}]}]}, {"title": "Baseline - prepared to talk with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.7", "spread": "0.9"}]}]}, {"title": "Baseline - prepared to talk with partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.5", "spread": "0.7"}]}]}, {"title": "Baseline - prepared to talk about children's future needs", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.5", "spread": "0.7"}]}]}, {"title": "Baseline - understand partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.4", "spread": "0.7"}]}]}, {"title": "Baseline - spending time with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.6", "spread": "1.4"}]}]}, {"title": "Baseline - prior conversations with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.9", "spread": "1.0"}]}]}, {"title": "7 Days - comfort talking with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6", "spread": "0.8"}]}]}, {"title": "7 Days - comfort talking with partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.2", "spread": "0.4"}]}]}, {"title": "7 Days - comfort talking about children's future needs", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.5", "spread": "0.5"}]}]}, {"title": "7 Days - prepared to talk with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.5", "spread": "1.0"}]}]}, {"title": "7 Days - prepared to talk with partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "spread": "0.5"}]}]}, {"title": "7 Days - prepared to talk about children's future needs", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "spread": "0.5"}]}]}, {"title": "7 Days - understand partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.4", "spread": "0.5"}]}]}, {"title": "7 Days - spending time with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.6", "spread": "0.7"}]}]}, {"title": "7 Days - prior conversations with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "0.9"}]}]}, {"title": "14 Days - comfort talking with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "1.0"}]}]}, {"title": "14 Days - comfort talking with partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "0.6"}]}]}, {"title": "14 Days - comfort talking about children's future needs", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "0.6"}]}]}, {"title": "14 Days - prepared to talk with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "0.6"}]}]}, {"title": "14 Days - prepared to talk with partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "spread": "0.5"}]}]}, {"title": "14 Days - prepared to talk about children's future needs", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "spread": "0.5"}]}]}, {"title": "14 Days - understand partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.1", "spread": "0.4"}]}]}, {"title": "14 Days - spending time with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.1", "spread": "0.7"}]}]}, {"title": "14 Days - prior conversations with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.1", "spread": "0.9"}]}]}, {"title": "28 Days - comfort talking with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "0.8"}]}]}, {"title": "28 Days - comfort talking with partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "spread": "0.5"}]}]}, {"title": "28 Days - comfort talking about children's future needs", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "spread": "0.5"}]}]}, {"title": "28 Days - prepared to talk with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "0.8"}]}]}, {"title": "28 Days - prepared to talk with partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "1.0"}]}]}, {"title": "28 Days - prepared to talk about children's future needs", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "1.0"}]}]}, {"title": "28 Days - understand partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "1.0"}]}]}, {"title": "28 Days - spending time with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.5", "spread": "0.6"}]}]}, {"title": "28 Days - prior conversations with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "1.2"}]}]}, {"title": "42 Days - comfort talking with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "42 Days - comfort talking with partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "42 Days - comfort talking about children's future needs", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "42 Days - prepared to talk with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "42 Days - prepared to talk with partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "42 Days - prepared to talk about children's future needs", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "42 Days - understand partner", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "42 Days - spending time with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "42 Days - prior conversations with children", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Not available. The protocol does not require adverse event assessment.", "description": "The protocol does not require adverse event assessment. Adverse Event Data was not collected.", "eventGroups": [{"id": "EG000", "title": "FAMILY", "description": "Patient-co-parent dyads will participate in the FAMILY intervention in-person.\n\nFAMILY Intervention: The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials.", "deathsNumAffected": 0, "deathsNumAtRisk": 0, "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Early termination due to COVID-19 pandemic limiting research enrollment"}, "certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Zev Nakamura, MD", "organization": "University of North Carolina at Chapel Hill", "email": "zev_nakamura@med.unc.edu", "phone": "984-974-3829"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2020-12-07", "uploadDate": "2023-04-16T09:31", "filename": "Prot_SAP_000.pdf", "size": 461606}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2020-12-14", "uploadDate": "2023-04-13T21:53", "filename": "ICF_001.pdf", "size": 173166}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-09-18"}, "conditionBrowseModule": {"meshes": [{"id": "D001943", "term": "Breast Neoplasms"}], "ancestors": [{"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D001941", "term": "Breast Diseases"}, {"id": "D012871", "term": "Skin Diseases"}, {"id": "D017437", "term": "Skin and Connective Tissue Diseases"}]}}, "hasResults": true}
{"protocolSection": {"identificationModule": {"nctId": "NCT05417516", "orgStudyIdInfo": {"id": "OCOG-2022-RAPID2"}, "organization": {"fullName": "Ontario Clinical Oncology Group (OCOG)", "class": "OTHER"}, "briefTitle": "A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)", "officialTitle": "A Randomized Trial of Five-Fraction Partial Breast Irradiation (RAPID2)"}, "statusModule": {"statusVerifiedDate": "2025-08", "overallStatus": "RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2023-11-20", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2029-11", "type": "ESTIMATED"}, "completionDateStruct": {"date": "2031-11", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2022-06-07", "studyFirstSubmitQcDate": "2022-06-09", "studyFirstPostDateStruct": {"date": "2022-06-14", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2025-08-14", "lastUpdatePostDateStruct": {"date": "2025-08-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Ontario Clinical Oncology Group (OCOG)", "class": "OTHER"}, "collaborators": [{"name": "GenesisCare AU", "class": "UNKNOWN"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The primary objective of this study is to determine in women with node negative BC 3cm in size, if PBI compared to WBI, both given once-a-day over 1 week following BCS, is non-inferior for LR and reduces adverse cosmesis. The primary outcomes are LR and patient-assessed cosmesis at 3 years post randomization.", "detailedDescription": "This is a randomized, two-arm, single blinded trial comparing two radiation treatment modalities, PBI and WBI. Following BCS or on the completion of additional adjuvant chemotherapy, eligible and consenting patients with newly diagnosed and histologically confirmed invasive carcinoma of the breast (without evidence of metastatic disease); with microscopically clear resection margins of 1mm (or no residual disease on re-excision) and negative axillary node involvement will be randomized in a 1:1 fashion to receive either PBI (experimental group) or WBI (control group). Study participants will receive 26Gy in 5 fractions in both treatment arms, treated once per day, for a period of 5-7 days. Study participants will not be made aware of treatment allocation to prevent any potential bias in their assessment of cosmesis. Stratification factors include tumour size, estrogen receptor (ER) status, and clinical centre."}, "conditionsModule": {"conditions": ["Breast Neoplasm Female", "Radiotherapy", "Cosmetic Outcome"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "maskingDescription": "Study participants will be made unaware of treatment allocation to prevent any potential bias in their assessment of cosmesis.", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 910, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Whole Breast Irradiation (WBI)", "type": "ACTIVE_COMPARATOR", "description": "26 Gy in 5 fractions to the whole breast", "interventionNames": ["Radiation: Whole Breast Irradiation (WBI)"]}, {"label": "Partial Breast Irradiation (PBI)", "type": "EXPERIMENTAL", "description": "26 Gy in 5 fractions to the tumour bed with a margin of normal tissue", "interventionNames": ["Radiation: Partial Breast Irradiation (PBI)"]}], "interventions": [{"type": "RADIATION", "name": "Whole Breast Irradiation (WBI)", "description": "The dose fractionation and prescription is 26Gy in 5 fractions to the PTV once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).", "armGroupLabels": ["Whole Breast Irradiation (WBI)"]}, {"type": "RADIATION", "name": "Partial Breast Irradiation (PBI)", "description": "The dose fractionation and prescription is 26Gy in 5 fractions to the PTV prescribed at the isocentre of the treatment fields treated once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).", "armGroupLabels": ["Partial Breast Irradiation (PBI)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Local Recurrence", "description": "Time from randomization to any evidence of tumour recurrence (invasive and non-invasive) in the treated breast.", "timeFrame": "Annually for 5 years post-randomization"}, {"measure": "Patient Assessment Cosmesis at 3 years", "description": "Cosmesis will be assessed by the patient using the Breast Cosmesis Questionnaire which incorporates the Modified EORTC Breast Cosmetic Rating System and the UK Patient Reported Outcomes Questions following BCS.", "timeFrame": "3 and 5 years post-randomization"}], "secondaryOutcomes": [{"measure": "Distant Disease Free Survival (DDSF)", "description": "Time from randomization to evidence of metastasis involving distant sites (e.g. bone, liver, lung, or brain).", "timeFrame": "Annually for 5 years post-randomization."}, {"measure": "Disease Free Survival (DFS)", "description": "Time from randomization to local recurrence, regional or distant recurrence, contralateral breast cancer, other second cancer, or death.", "timeFrame": "Annually for 5 years post-randomization."}, {"measure": "Overall Survival", "description": "Time from randomization to death of any cause.", "timeFrame": "3 years post-randomizaton."}, {"measure": "Radiation Toxicity", "description": "Acute (2 weeks and up to 3 months after completing RT) and late toxicity (beyond the 3 months after completing RT) will be assessed by clinical centre personnel using the NCI CTCAE version 5.0.", "timeFrame": "2 weeks and 3 months post-radiation treatment, then annually for 5 years post-randomization."}, {"measure": "Nurse/Clinical Research Associate assessed cosmesis at 3 and 5 years.", "description": "A nurse/Clinical Research Associate (CRA) assessment of cosmesis using the EORTC Breast Cosmetic Rating System. Nurses and CRAs will be training in assessing cosmesis using training slides and guide previously developed for other trials.", "timeFrame": "3 and 5 years post-randomization."}, {"measure": "Patient Assessed Cosmesis at 5 years.", "description": "Cosmesis will be assessed by the patient using the Breast Cosmesis Questionnaire which incorporates the Modified EORTC Breast Cosmetic Rating System13,27,42 and the UK Patient Reported Outcomes Questions following BCS.", "timeFrame": "5 years post-randomization."}, {"measure": "Patient Reported Quality of Life", "description": "Patients will complete the EORTC Breast Cancer Quality of life questionnaire", "timeFrame": "2 weeks post-radiation treatment, then at 3 and 5 years post-randomization."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nFor inclusion in this study, patients must fulfill all of the following criteria:\n\n1. Female with a new histological diagnosis of invasive carcinoma of the breast with no evidence of metastatic disease (see AJCC TNM Cancer Staging, Appendix II).\n2. Treated by BCS with microscopically clear resection margins \\>= 1mm for invasive and non-invasive disease or no residual disease on re-excision.\n3. Negative axillary node involvement as determined by either sentinel lymph node biopsy or axillary node dissection or clinical assessment with a negative axillary ultrasound and/or biopsy, for women with unifocal tumours \\<= 2cm, histologic grade 1 or 2, ER or PR+ and HER2-ve that are being planned for endocrine therapy\n\nExclusion Criteria:\n\nPatients who satisfy any of the following exclusion criteria are NOT eligible for this study:\n\n1. Age less than 50 years.\n2. Known to be BRCA 1 and/or BRCA 2 positive.\n3. Tumour size \\>3cm in greatest diameter on pathological examination.\n4. Evidence of extensive intraductal component (EIC) (defined as an invasive tumour with a ductal carcinoma in situ (DCIS) component comprising at least 25% and extending beyond the invasive component to surrounding normal breast tissue) with the following exception: smaller tumours with EIC where the combined size (of the invasive and DCIS components) are \\<= 3cm remain eligible\n5. Evidence of a DCIS component \\> 3cm\n6. Lobular carcinoma only.\n7. More than one primary tumour in different quadrants of the same breast (patients with multifocal breast cancer are eligible).\n8. Synchronous or previous contralateral breast cancer (patients with contralateral DCIS or LCIS are eligible).\n9. History of non-breast malignancy within the last 5 years other than treated non-melanoma skin cancer or treated in-situ carcinoma.\n10. Known pregnancy or currently lactating.\n11. Inability to localize tumour bed on CT planning (no evidence of surgical clips or seroma).\n12. Inability to plan the patient for the experimental technique.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "50 Years", "maximumAge": "120 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Shelley Chambers, MA", "role": "CONTACT", "phone": "905-527-2299", "phoneExt": "42618", "email": "schamber@mcmaster.ca"}, {"name": "Erin McGean", "role": "CONTACT", "phone": "905-527-2299", "phoneExt": "42656", "email": "mcgeane@mcmaster.ca"}], "overallOfficials": [{"name": "Timothy Whelan, M.D.", "affiliation": "Juravinski Cancer Centre and McMaster University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "GenesisCare Hurstville", "status": "RECRUITING", "city": "Hurstville", "state": "New South Wales", "zip": "2220", "country": "Australia", "contacts": [{"name": "Peter Graham", "role": "CONTACT", "phone": "+61 2 8568 7600", "email": "Peter.Graham@genesiscare.com"}, {"name": "Katerina Zavitsanou", "role": "CONTACT", "phone": "+61 2 8037 4112", "email": "Katerina.Zavitsanou@genesiscare.com"}, {"name": "Peter Graham", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -33.9677, "lon": 151.10149}}, {"facility": "GenesisCare Mater Hospital", "status": "NOT_YET_RECRUITING", "city": "North Sydney", "state": "New South Wales", "zip": "2060", "country": "Australia", "contacts": [{"name": "Gillian Lamoury", "role": "CONTACT", "phone": "(02) 9458 8050", "email": "Gillian.Lamoury@genesiscare.com"}, {"name": "Gillian Lamoury", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -33.839, "lon": 151.2072}}, {"facility": "GenesisCare Bundaberg", "status": "RECRUITING", "city": "Bundaberg", "state": "Queensland", "zip": "4670", "country": "Australia", "contacts": [{"name": "Gerry Adams", "role": "CONTACT", "phone": "(07) 4154 9900", "email": "Gerry.Adams@genesiscare.com"}, {"name": "Carla Kerr", "role": "CONTACT", "email": "carla.kerr@genesiscare.com"}, {"name": "Gerry Adams", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -24.86621, "lon": 152.3479}}, {"facility": "GenesisCare Southport", "status": "NOT_YET_RECRUITING", "city": "Southport", "state": "Queensland", "zip": "4215", "country": "Australia", "contacts": [{"name": "Tulasi Ramanarasiah", "role": "CONTACT", "phone": "(07) 5552 1400", "email": "tulasi@genesiscare.com"}, {"name": "Tulasi Ramanarasiah", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -27.96724, "lon": 153.39796}}, {"facility": "GenesisCare Tugun", "status": "RECRUITING", "city": "Tugun", "state": "Queensland", "zip": "4224", "country": "Australia", "contacts": [{"name": "Tulasi Ramanarasiah", "role": "CONTACT", "phone": "(07) 5507 3600", "email": "tulasi@genesiscare.com"}, {"name": "Kristy Longhurst", "role": "CONTACT", "email": "kristy.longhurst@genesiscare.com"}, {"name": "Tulasi Ramanarasiah", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -28.15, "lon": 153.5}}, {"facility": "GenesisCare St Andrew's", "status": "RECRUITING", "city": "Adelaide", "state": "South Australia", "zip": "5000", "country": "Australia", "contacts": [{"name": "Marcus Dreosti", "role": "CONTACT", "phone": "(08) 8228 6700", "email": "Marcus.Dreosti@genesiscare.com"}, {"name": "Isabelle Baldock", "role": "CONTACT", "email": "isabelle.baldock@genesiscare.com"}, {"name": "Marcus Dreosti", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -34.92866, "lon": 138.59863}}, {"facility": "GenesisCare Fiona Stanley Hospital", "status": "RECRUITING", "city": "Murdoch", "state": "Western Austrailia", "zip": "6150", "country": "Australia", "contacts": [{"name": "Yvonne Zissiadis", "role": "CONTACT", "phone": "(08) 6318 2882", "email": "Yvonne.Zissiadis@genesiscare.com"}, {"name": "Danica Old", "role": "CONTACT", "email": "danica.old@genesiscare.com"}, {"name": "Yvonne Zissiadis", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -32.06987, "lon": 115.83757}}, {"facility": "GenesisCare Hollywood", "status": "NOT_YET_RECRUITING", "city": "Nedlands", "state": "Western Australia", "zip": "6009", "country": "Australia", "contacts": [{"name": "Yvonne Zissiadis", "role": "CONTACT", "phone": "(08) 9286 8800", "email": "Yvonne.Zissiadis@genesiscare.com"}, {"name": "Yvonne Zissiadis", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": -31.98184, "lon": 115.8073}}, {"facility": "Arthur J. E. Child Comprehensive Cancer Centre-Clinical Research Unit", "status": "RECRUITING", "city": "Calgary", "state": "Alberta", "country": "Canada", "contacts": [{"name": "Payal Thakker", "role": "CONTACT", "email": "payal.thakkar@ahs.ca"}, {"name": "Marny Yar", "role": "CONTACT", "email": "marny.yar@ahs.ca"}, {"name": "Jeffrey Cao", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "BCCA-Vancouver Island Cancer Centre", "status": "NOT_YET_RECRUITING", "city": "Victoria", "state": "British Columbia", "country": "Canada", "geoPoint": {"lat": 48.4359, "lon": -123.35155}}, {"facility": "QEII HSC - Nova Scotia Cancer Centre", "status": "RECRUITING", "city": "Halifax", "state": "Nova Scotia", "country": "Canada", "contacts": [{"name": "Maureen Nolan", "role": "CONTACT"}, {"name": "Maureen Nolan", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 44.64269, "lon": -63.57688}}, {"facility": "Royal Victoria Regional Health Centre", "status": "RECRUITING", "city": "Barrie", "state": "Ontario", "country": "Canada", "contacts": [{"name": "Sujata Pokhrel", "role": "CONTACT", "email": "pokhrels@rvh.on.ca"}, {"name": "Christine DiMarco", "role": "CONTACT", "email": "dimarcoc@rvh.on.ca"}, {"name": "Jessica Conway", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 44.40011, "lon": -79.66634}}, {"facility": "Juravinski Cancer Centre", "status": "RECRUITING", "city": "Hamilton", "state": "Ontario", "country": "Canada", "contacts": [{"name": "Theresa Stokes", "role": "CONTACT", "email": "stokest@hhsc.ca"}, {"name": "Claire Howe", "role": "CONTACT", "email": "howe@hhsc.ca"}, {"name": "Do-Hoon Kim", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "London Regional Cancer Centre", "status": "RECRUITING", "city": "London", "state": "Ontario", "country": "Canada", "contacts": [{"name": "Amanda Anderson", "role": "CONTACT", "email": "Amanda.Anderson@lhsc.on.ca"}, {"name": "Francisco Perera, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 42.98339, "lon": -81.23304}}, {"facility": "Stronach (Southlake) Regional Health Centre", "status": "RECRUITING", "city": "Newmarket", "state": "Ontario", "country": "Canada", "contacts": [{"name": "Rachel Woo", "role": "CONTACT", "email": "RWoo@southlake.ca"}, {"name": "Kendra", "role": "CONTACT", "email": "KSinnesael@southlake.ca"}, {"name": "Tatiana Conrad", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 44.05011, "lon": -79.46631}}, {"facility": "Algoma District Cancer Program", "status": "RECRUITING", "city": "Sault Ste. Marie", "state": "Ontario", "country": "Canada", "contacts": [{"name": "Natalie Walde", "role": "CONTACT", "email": "walden@sah.on.ca"}, {"name": "Stephane Thibodeau", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 46.51677, "lon": -84.33325}}, {"facility": "Princess Margaret Hospital", "status": "RECRUITING", "city": "Toronto", "state": "Ontario", "country": "Canada", "contacts": [{"name": "Jemima Macadangdang", "role": "CONTACT", "email": "Jemima.Macadangdang@uhn.ca"}, {"name": "Jennifer Croke", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 43.70643, "lon": -79.39864}}, {"facility": "Toronto-Sunnybrook Health Sciences Centre - Odette Cancer Centre", "status": "RECRUITING", "city": "Toronto", "state": "Ontario", "country": "Canada", "contacts": [{"name": "Clarissa Chau", "role": "CONTACT", "email": "clarissa.chau@sunnybrook.ca"}], "geoPoint": {"lat": 43.70643, "lon": -79.39864}}, {"facility": "Windsor Regional Cancer Centre", "status": "RECRUITING", "city": "Windsor", "state": "Ontario", "zip": "N8W2X3", "country": "Canada", "contacts": [{"name": "Donna Clinansmith", "role": "CONTACT", "phone": "519-253-5253", "email": "Donna.Clinansmith@wrh.on.ca"}, {"name": "Khalid Hirmiz, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 42.30008, "lon": -83.01654}}, {"facility": "CSSS Champlain - Charles LeMoyne", "status": "RECRUITING", "city": "Greenfield Park", "state": "Quebec", "country": "Canada", "contacts": [{"name": "Lorraine Menard", "role": "CONTACT", "email": "lorraine.menard.cisssmc16@ssss.gouv.qc.ca"}, {"name": "Marjory Jolicoeur, MD", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 45.48649, "lon": -73.46223}}, {"facility": "McGill University Health Centre", "status": "RECRUITING", "city": "Montreal", "state": "Quebec", "country": "Canada", "contacts": [{"name": "Marianna Perna", "role": "CONTACT", "email": "marianna.perna@muhc.mcgill.ca"}, {"name": "Tatiana Carvalho", "role": "CONTACT", "email": "tatana.carvalho@muhc.mcgill.ca"}, {"name": "Tarek Hijal", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "CHUQ-Pavillon Hotel-Dieu de Quebec", "status": "RECRUITING", "city": "Qubec", "state": "Quebec", "country": "Canada", "contacts": [{"name": "Josee Allard", "role": "CONTACT", "email": "Josee.Allard@chudequebec.ca"}, {"name": "Valerie Theberge", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Centre Intgr Universitaire de Sant et de Services Sociaux de la Mauricie-Centre-du-Qubec (CIUSSS MCQ)", "status": "RECRUITING", "city": "Trois-Rivires", "state": "Quebec", "zip": "G8Z 3R9", "country": "Canada", "contacts": [{"name": "Marie-Eve Caron", "role": "CONTACT", "phone": "819-697-3333", "phoneExt": "63238", "email": "marie-eve_caron_chrtr@ssss.gouv.qc.ca"}, {"name": "Anne-Marie Taboika McMurray", "role": "CONTACT", "email": "anne-marie.taboika@ssss.gouv.qc.ca"}, {"name": "Francois Vincent", "role": "PRINCIPAL_INVESTIGATOR"}], "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "Saskatoon Cancer Centre", "status": "NOT_YET_RECRUITING", "city": "Saskatoon", "state": "Saskatchewan", "country": "Canada", "geoPoint": {"lat": 52.13238, "lon": -106.66892}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-09-18"}}, "hasResults": false}
{"protocolSection": {"identificationModule": {"nctId": "NCT02438358", "orgStudyIdInfo": {"id": "LUM-015/2.6-001"}, "secondaryIdInfos": [{"id": "1R21CA173762", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/1R21CA173762"}], "organization": {"fullName": "Lumicell, Inc.", "class": "INDUSTRY"}, "briefTitle": "Feasibility Study of Intraoperative Imaging in Breast Cancer", "officialTitle": "Feasibility of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects With Breast Cancer"}, "statusModule": {"statusVerifiedDate": "2022-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-06"}, "primaryCompletionDateStruct": {"date": "2017-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-04-17", "studyFirstSubmitQcDate": "2015-05-05", "studyFirstPostDateStruct": {"date": "2015-05-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2022-09-20", "resultsFirstSubmitQcDate": "2022-12-12", "resultsFirstPostDateStruct": {"date": "2023-01-05", "type": "ACTUAL"}, "dispFirstSubmitDate": "2018-10-30", "dispFirstSubmitQcDate": "2018-10-31", "dispFirstPostDateStruct": {"date": "2018-11-02", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-12-12", "lastUpdatePostDateStruct": {"date": "2023-01-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Lumicell, Inc.", "class": "INDUSTRY"}, "collaborators": [{"name": "National Cancer Institute (NCI)", "class": "NIH"}, {"name": "Massachusetts General Hospital", "class": "OTHER"}, {"name": "Dana-Farber Cancer Institute", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": true, "isUnapprovedDevice": true}, "descriptionModule": {"briefSummary": "For most breast cancer patients, surgery is the primary treatment. When patients undergo a lumpectomy, it is difficult for the surgeon to determine the extent of the tumor which results in incomplete tumor removal as determined by a positive margin assessment several days after the initial surgery is completed. Most patients with positive margins will undergo a second or even a third surgery to complete the tumor removal. The investigators hypothesize that the LUM Imaging System can reduce the rates of positive margins and, thus, the rates of second surgeries by identifying microscopic residual cancer in the tumor bed.\n\nThis is a non-randomized, open label study to evaluate the safety and efficacy of an intraoperative imaging system, the LUM Imaging System (LUM015 in conjunction with LUM 2.6 Imaging Device), in identifying residual cancer in the tumor bed of female breast cancer subjects. The study is composed of a Feasibility Trial divided into two phases: Phase A (15 total subjects) and Phase B (up to 50 total subjects). During Phase A, 15 subjects will be evaluated to collect additional patient safety data, select the dose of LUM015 for Phase B and evaluate the device function. During Phase B, subjects will be injected with LUM015 at the dose determined during Phase A to preliminarily assess the performance of the detection algorithm against pathology margin assessment. In Phase B, the surgeon will perform standard of care surgery and then use the LUM Imaging System to guide the removal of additional cavity shavings as indicated by the LUM Imaging System.", "detailedDescription": "The LUM Imaging System consists of the cancer imaging agent LUM015 and a hand-held fluorescence-based imager that collects the emission of activated LUM015 in and around tumor. The LUM Imaging System is designed to detect microscopic residual cancer cells in real-time within the tumor bed. In this study, we will evaluate the performance of the LUM Imaging System in detecting residual cancer and guiding its removal during lumpectomies.\n\nIn Phase A, all patients will receive standard of care surgery followed by intraoperative imaging of the tumor bed and resected tissue with the LUM 2.6 Imaging Device. In Phase A, no clinical decisions are made based on the imaging results. Standard of care margin assessment will be performed and compared against the imaging results with the LUM Imaging System.\n\nSubjects in Phase B will receive standard of care surgery followed by intraoperative imaging of the tumor bed with the LUM Imaging System. In Phase B, the surgeon will remove an additional shaved margin specimen if indicated by the LUM Imaging System. Final margin assessment will be performed on the very last shaved margin specimen removed.\n\nAll participating subjects will be observed to collect safety data from the time of injection of LUM015 to the time the clinical team decides no additional surgery is needed."}, "conditionsModule": {"conditions": ["Breast Cancer"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 60, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LUM Imaging System", "type": "EXPERIMENTAL", "description": "No dose or a single dose of LUM015 (0.5 mg/kg or 1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. The dose administered in Phase B will be determined based on results of Phase A. All subjects will have intraoperative imaging using the LUM 2.6 Imaging Device.", "interventionNames": ["Drug: LUM015", "Device: LUM 2.6 Imaging Device"]}], "interventions": [{"type": "DRUG", "name": "LUM015", "armGroupLabels": ["LUM Imaging System"]}, {"type": "DEVICE", "name": "LUM 2.6 Imaging Device", "armGroupLabels": ["LUM Imaging System"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "(Phase A Only) Selection of Dose of LUM015 to be Used in Future Breast Trials", "description": "tumor-to-normal tissue signal ratio as a function of dose of LUM015", "timeFrame": "1 day"}, {"measure": "(Phase B Only)Sensitivity and Specificity of the Lumicell Imaging System for Detecting Cancer", "description": "Data from the participants in Phase A was used to develop an initial tumor detection algorithm that was then tested in Phase B. Thus, this endpoint is only applicable to the participants enrolled in the Phase B portion of the study.\n\nThis endpoint measures the ability of the system to detect cancer as measured by sensitivity and specificity as defined below:\n\nSensitivity = \\[number of true positives/(number of true positives + number of false negatives)\\] x 100% Specificity = \\[number of true negatives/(number of true negatives + number of false positives)\\] x 100%\n\nTrue positives = positive signal from imaging system and cancer found in tissue by pathology False positives = positive signal from imaging system and no cancer found in tissue by pathology True negatives = negative signal from imaging system and no cancer found in tissue by pathology False negatives = negative signal from imaging system and cancer found in tissue by pathology", "timeFrame": "1 day"}], "secondaryOutcomes": [{"measure": "Number of Patients With Adverse Events as a Measure of Safety of the LUM Imaging System in Breast Cancer Subjects.", "description": "Serious Adverse Events: Include adverse events that result in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.\n\nNon-Serious Adverse Events: Adverse events that are not Serious Adverse Events.", "timeFrame": "Patients were evaluated for adverse events from time of injection until standard post-surgery follow-up visit. (Median 31 days after lumpectomy)."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed primary breast cancer.\n* Female, age of 18 years or older.\n* Scheduled for a lumpectomy of a breast tumor.\n* Able and willing to follow study procedures and instructions.\n* Subjects must have received and signed an informed consent form.\n* Subjects must be otherwise healthy except for the diagnosis of cancer, as per the exclusion criteria listed below.\n* Subjects must have normal organ and marrow function as defined below:\n\n  * Leukocytes \\> 3,000/mcL\n  * Absolute neutrophil count \\> 1,500/mcL\n  * Platelets \\> 100,000/mcL\n  * total bilirubin within normal institutional limits\n  * AST (SGOT)/ALT (SGPT) \\< 2.5 X institutional upper limit of normal\n  * Creatinine within normal institutional limits or creatinine clearance \\> 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.\n* Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) starting the day entering the study, and for 60 days after injection of the imaging agent.\n* Subjects with ECOG performance status of 0 or 1.\n\nExclusion Criteria:\n\n* Subjects with a known current condition of substance addiction.\n* Subjects who have taken an investigational drug within 30 days of enrollment.\n* Subjects with prolonged QT interval.\n* Subjects who will have administration of methylene blue or any blue dye used for sentinel node mapping procedures.\n* Subjects who have not recovered from adverse events due to pharmaceutical or diagnostic agents administered more than 4 weeks earlier.\n* Subjects with uncontrolled hypertension defined as persistent systolic blood pressure \\> 150 mm Hg, or diastolic blood pressure \\> 95 mm Hg; those subjects with known HTN should be stable within these ranges while under pharmaceutical therapy\n* Subjects with insulin dependent diabetes mellitus.\n* History of anaphylactic reaction attributed to any contrast agent or drugs containing polyethylene glycol (PEG).\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, COPD or asthma requiring hospitalization within the past 12 months, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Pregnant women are excluded. Breastfeeding should be discontinued if the mother is treated with LUM015.\n* Subjects who are sexually active and not willing/able to use medically acceptable forms of contraception upon entering the study.\n* HIV-positive individuals on combination antiretroviral therapy.\n* Any subject for whom the investigator feels participation is not in the best interest of the subject.\n* Subjects undergoing a second surgery because they had positive margins in a previous surgery.\n* Subjects with prior breast surgeries, mastectomies, breast reconstructions or implants. (Note: subjects who have had prior breast biopsies are not excluded)\n* Subjects with prior reduction mammoplasties or breast reductions performed less than 2 years prior to enrollment to this study.\n* Subjects previously treated with systemic therapies to treat cancer, such as neo-adjuvant chemotherapy or hormonal therapy.", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Barbara L Smith, M.D., Ph.D.", "affiliation": "Massachusetts General Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Massachusetts General Hospital", "city": "Boston", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Phase A enrolled 15 women undergoing lumpectomy for primary breast cancers assigned sequentially to one of the 3 different dose arms (no dose of LUM015, 0.5mg/kg of LUM015, and 1.0mg/kg of LUM015).\n\nPhase B patients enrolled until 10 patients had positive margins in their standard of care cavity shave or a maximum of 50 patients was reached, whichever happened first.", "groups": [{"id": "FG000", "title": "Phase A: No Dose", "description": "5 participants were not injected with LUM015. All subjects will have intraoperative imaging using the LUM 2.6 Imaging Device."}, {"id": "FG001", "title": "Phase A: LUM015 0.5 mg/kg", "description": "5 participants received a single dose of LUM015 0.5 mg/kg administered by intravenous injection between 2 to 6 hours prior to surgery. All subjects will have intraoperative imaging using the LUM 2.6 Imaging Device."}, {"id": "FG002", "title": "Phase A: LUM015 1.0 mg/kg", "description": "5 participants received a single dose of LUM015 1.0 mg/kg administered by intravenous injection between 2 to 6 hours prior to surgery. All subjects will have intraoperative imaging using the LUM 2.6 Imaging Device."}, {"id": "FG003", "title": "Phase B: LUM015 1.0 mg/kg", "description": "45 participants received a single dose of LUM015 1.0 mg/kg administered by intravenous injection between 2 to 6 hours prior to surgery. All subjects will have intraoperative imaging using the LUM 2.6 Imaging Device."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "45"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "44"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Phase A: No Dose", "description": "5 participants were not administered with LLUM015 All participants will have intraoperative imaging using the LUM 2.6 Imaging Device."}, {"id": "BG001", "title": "Phase A: LUM015 0.5 mg/kg", "description": "5 participants were administered with LLUM015 at 0.5 mg/kg by intravenous injection between 2 to 6 hours prior to surgery.\n\nAll participants will have intraoperative imaging using the LUM 2.6 Imaging Device."}, {"id": "BG002", "title": "Phase A: LUM015 1.0 mg/kg", "description": "5 participants were administered with LLUM015 at 1.0 mg/kg by intravenous injection between 2 to 6 hours prior to surgery.\n\nAll participants will have intraoperative imaging using the LUM 2.6 Imaging Device."}, {"id": "BG003", "title": "Phase B: LUM015 1.0 mg/kg", "description": "45 participants were administered with a single dose of LUM015 at 1.0mg/kg by intravenous injection between 2 and 6 hours prior to surgery. Patients will then undergo lumpectomy followed by LUM imagining of the lumpectomy cavity. Comprehensive shaves will be performed followed by LUM015 imagining of the resulting cavity and resection of LUM-imagining-positive cavity tissue."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "69", "lowerLimit": "56", "upperLimit": "78"}, {"groupId": "BG001", "value": "65", "lowerLimit": "48", "upperLimit": "70"}, {"groupId": "BG002", "value": "59", "lowerLimit": "48", "upperLimit": "78"}, {"groupId": "BG003", "value": "60", "lowerLimit": "44", "upperLimit": "79"}, {"groupId": "BG004", "value": "60", "lowerLimit": "44", "upperLimit": "79"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "39"}, {"groupId": "BG004", "value": "54"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "6"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "2"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "5"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "38"}, {"groupId": "BG004", "value": "53"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}]}]}, {"title": "Cancer Histologic Type (from surgical excision)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Invasive Ductal Carcinoma with or without Ductal Carcinoma In Situ", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "27"}, {"groupId": "BG004", "value": "36"}]}]}, {"title": "Invasive Lobular Carcinoma with or without Ductal Carcinoma In Situ", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "7"}]}]}, {"title": "Invasive Ductal Carcinoma and Invasive Lobular Carcinoma with or without Ductal Carcinoma In Situ", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "2"}]}]}, {"title": "Pure Ductal Carcinoma In Situ", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "13"}]}]}, {"title": "No Tumor Found", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "2"}]}]}]}, {"title": "Invasive Tumor Size in Largest Dimension", "populationDescription": "Not all patient tumors were measured.", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "cm", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "37"}, {"groupId": "BG004", "value": "48"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1", "lowerLimit": "0.6", "upperLimit": "1.3"}, {"groupId": "BG001", "value": "1.85", "lowerLimit": "0.9", "upperLimit": "1.9"}, {"groupId": "BG002", "value": "1.6", "lowerLimit": "0.4", "upperLimit": "2.5"}, {"groupId": "BG003", "value": "1.2", "lowerLimit": "0.1", "upperLimit": "3.5"}, {"groupId": "BG004", "value": "1.2", "lowerLimit": "0.1", "upperLimit": "3.5"}]}]}]}, {"title": "Patients with Node Positive Disease", "populationDescription": "Not all patients were diagnosed.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "7"}]}]}]}, {"title": "Tumor Receptors", "populationDescription": "Not all patients were diagnosed.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Her-2", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "30"}, {"groupId": "BG004", "value": "42"}]}], "categories": [{"title": "Positives", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "12"}]}, {"title": "Negatives", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "22"}, {"groupId": "BG004", "value": "30"}]}, {"title": "Neither triple negative nor triple positive", "measurements": [{"groupId": "BG000", "value": "NA", "comment": "Not applied"}, {"groupId": "BG001", "value": "NA", "comment": "Not applied"}, {"groupId": "BG002", "value": "NA", "comment": "Not applied"}, {"groupId": "BG003", "value": "NA", "comment": "Not applied"}, {"groupId": "BG004", "value": "NA", "comment": "Total not calculated because data are not available (NA) in one or more arms."}]}]}, {"title": "Estrogen Receptor (ER)", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "24"}, {"groupId": "BG004", "value": "39"}]}], "categories": [{"title": "Positives", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "19"}, {"groupId": "BG004", "value": "33"}]}, {"title": "Negatives", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "6"}]}, {"title": "Neither triple negative nor triple positive", "measurements": [{"groupId": "BG000", "value": "NA", "comment": "Not applied"}, {"groupId": "BG001", "value": "NA", "comment": "Not applied"}, {"groupId": "BG002", "value": "NA", "comment": "Not applied"}, {"groupId": "BG003", "value": "NA", "comment": "Not applied"}, {"groupId": "BG004", "value": "NA", "comment": "Total not calculated because data are not available (NA) in one or more arms."}]}]}, {"title": "Progesterone Receptor (PR)", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "24"}, {"groupId": "BG004", "value": "39"}]}], "categories": [{"title": "Positives", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "17"}, {"groupId": "BG004", "value": "31"}]}, {"title": "Negatives", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "8"}]}, {"title": "Neither triple negative nor triple positive", "measurements": [{"groupId": "BG000", "value": "NA", "comment": "Not applied"}, {"groupId": "BG001", "value": "NA", "comment": "Not applied"}, {"groupId": "BG002", "value": "NA", "comment": "Not applied"}, {"groupId": "BG003", "value": "NA", "comment": "Not applied"}, {"groupId": "BG004", "value": "NA", "comment": "Total not calculated because data are not available (NA) in one or more arms."}]}]}, {"title": "All Triple Her-2, ER, PR", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "23"}, {"groupId": "BG004", "value": "38"}]}], "categories": [{"title": "Positives", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "4"}]}, {"title": "Negatives", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "5"}]}, {"title": "Neither triple negative nor triple positive", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "19"}, {"groupId": "BG004", "value": "29"}]}]}]}, {"title": "Menopausal Status", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Post-menopause", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "14"}, {"groupId": "BG004", "value": "27"}]}]}, {"title": "Pre/Peri-menopause", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "31"}, {"groupId": "BG004", "value": "33"}]}]}]}, {"title": "Mammographic Breast Density", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Almost Entirely Fatty", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "3"}]}]}, {"title": "Scattered Areas of Fibroglandular/Heterogeneously Dense", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "18"}, {"groupId": "BG004", "value": "21"}]}]}, {"title": "Heterogeneously Dense", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "22"}, {"groupId": "BG004", "value": "31"}]}]}, {"title": "Extremely Dense", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "2"}]}]}, {"title": "Mixed Scattered Fibroglandular/Heterogeneously Dense", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "3"}]}]}]}, {"title": "Physical Examination Findings", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Palpable Mass", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "13"}, {"groupId": "BG004", "value": "16"}]}]}, {"title": "No Palpable Mass", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "45"}, {"groupId": "BG004", "value": "60"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "32"}, {"groupId": "BG004", "value": "44"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "(Phase A Only) Selection of Dose of LUM015 to be Used in Future Breast Trials", "description": "tumor-to-normal tissue signal ratio as a function of dose of LUM015", "populationDescription": "5 patients not injected with LUM015, 5 patients injected with LUM015 at 0.5 mg/kg, and 5 patients injected with LUM015 at 1.0 mg/kg.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "1 day", "groups": [{"id": "OG000", "title": "Phase A No LUM015", "description": "(Phase A only) 5 patients not injected with LUM015"}, {"id": "OG001", "title": "Phase A 0.5 mg/kg", "description": "(Phase A only) 5 patients injected with 0.5 mg/kg of LUM015"}, {"id": "OG002", "title": "Phase A 1.0 mg/kg", "description": "(Phase A only) 5 patients injected with 1.0 mg/kg of LUM015"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.1", "spread": "0.7"}, {"groupId": "OG001", "value": "4.7", "spread": "2.0"}, {"groupId": "OG002", "value": "4.2", "spread": "2.1"}]}]}]}, {"type": "PRIMARY", "title": "(Phase B Only)Sensitivity and Specificity of the Lumicell Imaging System for Detecting Cancer", "description": "Data from the participants in Phase A was used to develop an initial tumor detection algorithm that was then tested in Phase B. Thus, this endpoint is only applicable to the participants enrolled in the Phase B portion of the study.\n\nThis endpoint measures the ability of the system to detect cancer as measured by sensitivity and specificity as defined below:\n\nSensitivity = \\[number of true positives/(number of true positives + number of false negatives)\\] x 100% Specificity = \\[number of true negatives/(number of true negatives + number of false positives)\\] x 100%\n\nTrue positives = positive signal from imaging system and cancer found in tissue by pathology False positives = positive signal from imaging system and no cancer found in tissue by pathology True negatives = negative signal from imaging system and no cancer found in tissue by pathology False negatives = negative signal from imaging system and cancer found in tissue by pathology", "populationDescription": "Intent to treat population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of measurements", "timeFrame": "1 day", "groups": [{"id": "OG000", "title": "Phase B: LUM015 1.0 mg/kg", "description": "45 participants were administered with a single dose of LUM015 at 1.0mg/kg by intravenous injection between 2 and 6 hours prior to surgery. Patients will then undergo lumpectomy followed by LUM imagining of the lumpectomy cavity. Comprehensive shaves will be performed followed by LUM015 imagining of the resulting cavity and resection of LUM-imagining-positive cavity tissue."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}]}], "classes": [{"title": "Sensitivity", "categories": [{"measurements": [{"groupId": "OG000", "value": "84", "lowerLimit": "79.5", "upperLimit": "88.5"}]}]}, {"title": "Specificity", "categories": [{"measurements": [{"groupId": "OG000", "value": "73", "lowerLimit": "68.5", "upperLimit": "77.5"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Adverse Events as a Measure of Safety of the LUM Imaging System in Breast Cancer Subjects.", "description": "Serious Adverse Events: Include adverse events that result in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.\n\nNon-Serious Adverse Events: Adverse events that are not Serious Adverse Events.", "populationDescription": "Intent to treat population.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Patients were evaluated for adverse events from time of injection until standard post-surgery follow-up visit. (Median 31 days after lumpectomy).", "groups": [{"id": "OG000", "title": "Phase A: No Dose", "description": "5 participants were not administered with LLUM015 All participants will have intraoperative imaging using the LUM 2.6 Imaging Device."}, {"id": "OG001", "title": "Phase A: LUM015 0.5 mg/kg", "description": "5 participants were administered with LLUM015 at 0.5 mg/kg by intravenous injection between 2 to 6 hours prior to surgery.\n\nAll participants will have intraoperative imaging using the LUM 2.6 Imaging Device."}, {"id": "OG002", "title": "Phase A: LUM015 1.0 mg/kg", "description": "5 participants were administered with LLUM015 at 1.0 mg/kg by intravenous injection between 2 to 6 hours prior to surgery.\n\nAll participants will have intraoperative imaging using the LUM 2.6 Imaging Device."}, {"id": "OG003", "title": "Phase B: LUM015 1. mg/kg", "description": "45 participants were administered with a single dose of LUM015 at 1.0mg/kg by intravenous injection between 2 and 6 hours prior to surgery. Patients will then undergo lumpectomy followed by LUM imagining of the lumpectomy cavity. Comprehensive shaves will be performed followed by LUM015 imagining of the resulting cavity and resection of LUM-imagining-positive cavity tissue."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "45"}]}], "classes": [{"title": "Serious Adverse Event", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Non-Serious Adverse Event", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Patients were evaluated for adverse events from time of injection until standard psot-surgery follow-up visit. (Median 31 days after lumpectomy).", "eventGroups": [{"id": "EG000", "title": "Phase A: No Dose", "description": "5 participants were not administered with LUM015. All participants will have intraoperative imaging using the LUM 2.6 Imaging Device.", "deathsNumAffected": 0, "deathsNumAtRisk": 5, "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 0, "otherNumAtRisk": 5}, {"id": "EG001", "title": "Phase A: LUM015 0.5 mg/kg", "description": "5 participants were administered with a single dose of LUM015 at 0.5 mg/kg by intravenous injection between 2 and 6 hours prior to surgery. All participants will have intraoperative imaging using the LUM 2.6 Imaging Device.", "deathsNumAffected": 0, "deathsNumAtRisk": 5, "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 0, "otherNumAtRisk": 5}, {"id": "EG002", "title": "Phase A: LUM015 1.0 mg/kg", "description": "5 participants were administered with a single dose of LUM015 at 1.0 mg/kg by intravenous injection between 2 and 6 hours prior to surgery. All participants will have intraoperative imaging using the LUM 2.6 Imaging Device.", "deathsNumAffected": 0, "deathsNumAtRisk": 5, "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 0, "otherNumAtRisk": 5}, {"id": "EG003", "title": "Phase B: LUM015 1.0 mg/kg", "description": "45 participants were administered with a single dose of LUM015 at 1.0 mg/kg by intravenous injection between 2 and 6 hours prior to surgery. Participants will then undergo lumpectomy followed by LUM imagining of the lumpectomy cavity. Comprehensive shaves will be performed followed by LUM015 imagining of the resulting cavity and resection of LUM-imagining-positive cavity tissue.", "deathsNumAffected": 0, "deathsNumAtRisk": 45, "seriousNumAffected": 0, "seriousNumAtRisk": 45, "otherNumAffected": 5, "otherNumAtRisk": 45}], "otherEvents": [{"term": "Procedural Nausea", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 45}]}, {"term": "Post Procedural Hematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 45}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 45}]}, {"term": "Extravasation", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 45}]}, {"term": "Suture Related Complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 45}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "False positive readings may be associated with the LUM015 fluorescent signal extending beyond the tumor border, technical factors related to specimen processing and tissue sampling, and possible poor contact between the optical head and lumpectomy cavity wall, which may have reduced detection of fluorescent signal. This issues will be addressed in future clinical trials."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Jorge Ferrer, Ph.D.", "organization": "Lumicell", "email": "jmferrer@lumicell.com", "phone": "617-571-0592"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2016-08-02", "uploadDate": "2022-09-20T15:30", "filename": "Prot_SAP_000.pdf", "size": 1031086}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-09-18"}, "conditionBrowseModule": {"meshes": [{"id": "D001943", "term": "Breast Neoplasms"}], "ancestors": [{"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D001941", "term": "Breast Diseases"}, {"id": "D012871", "term": "Skin Diseases"}, {"id": "D017437", "term": "Skin and Connective Tissue Diseases"}]}}, "hasResults": true}
{"protocolSection": {"identificationModule": {"nctId": "NCT00386685", "orgStudyIdInfo": {"id": "TCD6595"}, "secondaryIdInfos": [{"id": "XRP9881"}], "organization": {"fullName": "Sanofi", "class": "INDUSTRY"}, "briefTitle": "XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer", "officialTitle": "Open Label, Uncontrolled Study of XRP9881 in Combination With Trastuzumab (Herceptin) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)"}, "statusModule": {"statusVerifiedDate": "2011-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-07"}, "primaryCompletionDateStruct": {"date": "2008-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-10-10", "studyFirstSubmitQcDate": "2006-10-10", "studyFirstPostDateStruct": {"date": "2006-10-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-04-11", "lastUpdatePostDateStruct": {"date": "2011-04-12", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Trial Transparency Team", "oldOrganization": "sanofi-aventis"}, "leadSponsor": {"name": "Sanofi", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The primary objective of the study is to assess the activity of XRP9881 in combination with trastuzumab.\n\nThe secondary objectives are safety and pharmacokinetic interaction"}, "conditionsModule": {"conditions": ["Breast Neoplasms"], "keywords": ["Cancer", "Breast", "metastatic breast cancer"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 51, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "larotaxel (XRP9881)", "description": "intravenous administration"}, {"type": "DRUG", "name": "trastuzumab", "description": "intravenous administration"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Response rate (best overall response under treatment)", "timeFrame": "study period"}], "secondaryOutcomes": [{"measure": "Incidence of grade 3-4 toxicities, pharmacokinetic interaction", "timeFrame": "study period"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Metastatic breast cancer (MBC)\n* HER2 (Human Epidermal Growth Factor Receptor 2) positive: FISH (Fluorescent In Situ Hybridization) positive or IHC (Immunohistochemistry) 3+\n* Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)\n* Adequate organs functions\n\nExclusion Criteria:\n\n* More than one previous chemotherapy regimen for metastatic disease\n* Cardiac dysfunction", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Henri Roche, PhD", "affiliation": "Institut Claudius Regaud - Toulouse - France", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Sanofi-Aventis Administrative Office", "city": "Diegem", "country": "Belgium", "geoPoint": {"lat": 50.89727, "lon": 4.43354}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Paris", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Bromma", "country": "Sweden", "geoPoint": {"lat": 59.34, "lon": 17.94}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Geneva", "country": "Switzerland", "geoPoint": {"lat": 46.20222, "lon": 6.14569}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-09-18"}, "conditionBrowseModule": {"meshes": [{"id": "D001943", "term": "Breast Neoplasms"}, {"id": "D009369", "term": "Neoplasms"}], "ancestors": [{"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D001941", "term": "Breast Diseases"}, {"id": "D012871", "term": "Skin Diseases"}, {"id": "D017437", "term": "Skin and Connective Tissue Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C531079", "term": "larotaxel"}, {"id": "D000068878", "term": "Trastuzumab"}], "ancestors": [{"id": "D061067", "term": "Antibodies, Monoclonal, Humanized"}, {"id": "D000911", "term": "Antibodies, Monoclonal"}, {"id": "D000906", "term": "Antibodies"}, {"id": "D007136", "term": "Immunoglobulins"}, {"id": "D007162", "term": "Immunoproteins"}, {"id": "D001798", "term": "Blood Proteins"}, {"id": "D011506", "term": "Proteins"}, {"id": "D000602", "term": "Amino Acids, Peptides, and Proteins"}, {"id": "D012712", "term": "Serum Globulins"}, {"id": "D005916", "term": "Globulins"}]}}, "hasResults": false}
{"protocolSection": {"identificationModule": {"nctId": "NCT00286117", "orgStudyIdInfo": {"id": "1033IT/0002"}, "secondaryIdInfos": [{"id": "ITA"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "ITA - Clinical Study Comparing ARIMIDEX With NOLVADEX in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years", "officialTitle": "An Open Randomised Clinical Study Comparing ARIMIDEX With NOLVADEX as Adjuvant Therapies in Post-Menopausal Women With Breast Cancer Already Being Treated With NOLVADEX for at Least Two Years"}, "statusModule": {"statusVerifiedDate": "2009-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "1998-03"}, "completionDateStruct": {"date": "2006-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-02-02", "studyFirstSubmitQcDate": "2006-02-02", "studyFirstPostDateStruct": {"date": "2006-02-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2009-04-30", "lastUpdatePostDateStruct": {"date": "2009-05-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Francisco Sapunar, MD - Arimidex Medical Science Director", "oldOrganization": "AstraZeneca"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Institute of Cancer Research, United Kingdom", "class": "OTHER"}]}, "descriptionModule": {"briefSummary": "The purpose of this study was to assess the difference in disease-free survival between post-menopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued on tamoxifen."}, "conditionsModule": {"conditions": ["Breast Cancer"], "keywords": ["Breast Cancer"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 448, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Anastrozole", "interventionNames": ["Drug: Anastrozole"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "Tamoxifen", "interventionNames": ["Drug: Tamoxifen"]}], "interventions": [{"type": "DRUG", "name": "Anastrozole", "description": "oral", "armGroupLabels": ["1"], "otherNames": ["Arimidex", "ZD1033"]}, {"type": "DRUG", "name": "Tamoxifen", "description": "oral", "armGroupLabels": ["2"], "otherNames": ["Nolvadex"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The primary objective of this analysis was to assess the difference in disease-free survival between post-menopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued on tamoxifen"}], "secondaryOutcomes": [{"measure": "Assess the difference in overall survival/disease recurrence/safety and tolerability between post-menopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Post-menopausal status; age 75 years;\n* histologically confirmed invasive breast cancer with metastases in the axillary lymph nodes;\n* oestrogen receptor status positive or unknown;\n* primary treatment (surgery +/- radiotherapy, +/- chemotherapy) completed\n\nExclusion Criteria:\n\n* Clinical evidence of metastatic disease (including local or remote recurrence, even if the patient appeared to be in complete remission at the time of randomisation).", "healthyVolunteers": false, "sex": "FEMALE", "maximumAge": "75 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "AstraZeneca Arimidex Medical Science Director, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}, {"name": "Francesco Boccardo, MD", "affiliation": "University and National Cancer Research Institute", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Arezzo", "country": "Italy", "geoPoint": {"lat": 43.46276, "lon": 11.88068}}, {"facility": "Research Site", "city": "Bologna", "country": "Italy", "geoPoint": {"lat": 44.49381, "lon": 11.33875}}, {"facility": "Research Site", "city": "Casalpusterlengo", "country": "Italy", "geoPoint": {"lat": 45.17921, "lon": 9.64834}}, {"facility": "Research Site", "city": "Catania", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"facility": "Research Site", "city": "Chieti", "country": "Italy", "geoPoint": {"lat": 42.34827, "lon": 14.16494}}, {"facility": "Research Site", "city": "Ferrara", "country": "Italy", "geoPoint": {"lat": 44.83804, "lon": 11.62057}}, {"facility": "Research Site", "city": "Florence", "country": "Italy", "geoPoint": {"lat": 43.77925, "lon": 11.24626}}, {"facility": "Research Site", "city": "Forl", "country": "Italy", "geoPoint": {"lat": 44.22177, "lon": 12.04144}}, {"facility": "Research Site", "city": "Genova", "country": "Italy", "geoPoint": {"lat": 45.21604, "lon": 11.87211}}, {"facility": "Research Site", "city": "Lugo", "country": "Italy", "geoPoint": {"lat": 44.42137, "lon": 11.91094}}, {"facility": "Research Site", "city": "Messina", "country": "Italy", "geoPoint": {"lat": 38.19394, "lon": 15.55256}}, {"facility": "Research Site", "city": "Milan", "country": "Italy", "geoPoint": {"lat": 42.78235, "lon": 12.59836}}, {"facility": "Research Site", "city": "Monserrato", "country": "Italy", "geoPoint": {"lat": 39.25642, "lon": 9.1444}}, {"facility": "Research Site", "city": "Palermo", "country": "Italy", "geoPoint": {"lat": 38.1166, "lon": 13.3636}}, {"facility": "Research Site", "city": "Pavia", "country": "Italy", "geoPoint": {"lat": 45.19205, "lon": 9.15917}}, {"facility": "Research Site", "city": "Pinerolo", "country": "Italy", "geoPoint": {"lat": 44.88534, "lon": 7.33135}}, {"facility": "Research Site", "city": "Roma", "country": "Italy", "geoPoint": {"lat": 44.99364, "lon": 11.10642}}, {"facility": "Research Site", "city": "Rovigo", "country": "Italy", "geoPoint": {"lat": 45.06982, "lon": 11.79022}}, {"facility": "Research Site", "city": "Sanremo", "country": "Italy", "geoPoint": {"lat": 43.81725, "lon": 7.7772}}, {"facility": "Research Site", "city": "Saronno", "country": "Italy", "geoPoint": {"lat": 45.62513, "lon": 9.03517}}, {"facility": "Research Site", "city": "Sassari", "country": "Italy", "geoPoint": {"lat": 40.72586, "lon": 8.55552}}, {"facility": "Research Site", "city": "Terni", "country": "Italy", "geoPoint": {"lat": 42.56335, "lon": 12.64329}}, {"facility": "Research Site", "city": "Torino", "country": "Italy", "geoPoint": {"lat": 44.88856, "lon": 11.99138}}, {"facility": "Research Site", "city": "Trieste", "country": "Italy", "geoPoint": {"lat": 45.64953, "lon": 13.77678}}, {"facility": "Research Site", "city": "Vicenza", "country": "Italy", "geoPoint": {"lat": 45.54672, "lon": 11.5475}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-09-18"}, "conditionBrowseModule": {"meshes": [{"id": "D001943", "term": "Breast Neoplasms"}], "ancestors": [{"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D001941", "term": "Breast Diseases"}, {"id": "D012871", "term": "Skin Diseases"}, {"id": "D017437", "term": "Skin and Connective Tissue Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077384", "term": "Anastrozole"}, {"id": "D013629", "term": "Tamoxifen"}], "ancestors": [{"id": "D009570", "term": "Nitriles"}, {"id": "D009930", "term": "Organic Chemicals"}, {"id": "D014230", "term": "Triazoles"}, {"id": "D001393", "term": "Azoles"}, {"id": "D006573", "term": "Heterocyclic Compounds, 1-Ring"}, {"id": "D006571", "term": "Heterocyclic Compounds"}, {"id": "D013267", "term": "Stilbenes"}, {"id": "D001597", "term": "Benzylidene Compounds"}, {"id": "D001555", "term": "Benzene Derivatives"}, {"id": "D006841", "term": "Hydrocarbons, Aromatic"}, {"id": "D006844", "term": "Hydrocarbons, Cyclic"}, {"id": "D006838", "term": "Hydrocarbons"}]}}, "hasResults": false}
